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ABSTRACT 
A simple, sensitive and reproducible spectrophotometric method for the analysis of Baricitinib in pure form and in its dosage form has been 
developed. Baricitinib is a synthetic antineoplastic and immunomodulating  drug. Baricitinib is a selective and reversible Janus kinase 1 (JAK1) 
and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway 
signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. Developed method obeyed beer’s law in a 
concentration range of 10-60 µg/ml with a correlation coefficient (R2) of 0.993. Quantification was carried out at 250 nm. Percentage assay of 
Baricitinib was found to be close to 100 %. The results of analysis have been validated statistically and recovery studies confirmed the accuracy 
of the proposed method. 
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INTRODUCTION: 
Baricitinib is chemically, 2-[1-(ethanesulfonyl)-3-(4-{7H-
pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-
yl]acetonitrile. It is used for the treatment of moderate to 
severe active rheumatoid arthritis in adult patients who have 
responded inadequately to, or who are intolerant to one or 
more disease-modifying anti-rheumatic drugs as 
monotherapy or in combination with methotrexate. Upon 
administration, baricitinib binds to JAK1/2, which inhibits 
JAK1/2 activation and leads to the inhibition of the JAK-
signal transducers and activators of transcription (STAT) 
signaling pathway. This decreases the production of 
inflammatory cytokines and may prevent an inflammatory 
response. In addition, baricitinib may induce apoptosis and 
reduce proliferation of JAK1/2-expressing tumor cells. JAK 
kinases are intracellular enzymes involved in cytokine 
signaling, inflammation, immune function and 
hematopoiesis; they are also upregulated and mutated in 
various tumor cell types. In February 2017, Baricitinib was 
approved for use in the EU as a second-line oral therapy for 
moderate to severe active rheumatoid arthritis in adults, 
either alone or in combination with methotrexate. It is 
marketed under the trade name Olumiant. [1-3]. The structure 
of Baricitinib is given in Fig 1. 
 
Fig 1: Structure of Baricitinib 
As per the literature survey the data shows that 
simultaneous quantification of Baricitinib and Methotrexate 
in rat plasma by LC-MS/MS is reported [4]. No spectroscopic 
method has been reported for estimation of baricitinib in 
bulk or dosage form. The present manuscript describes 
simple and sensitive spectroscopic procedure for the 
determination of baricitinib in accordance with International 
Conference on Harmonisation Guidelines.[5] 
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MATERIALS AND METHODS: 
CHEMICALS AND REAGENTS:  
Baricitinib bulk powder was kindly gifted by Bulat 
Pharmaceutical Pvt. Ltd. India. Methanol AR grade was 
purchased from S.D. Fine Chemical Laboratories, Mumbai 
and DMSO AR grade was purchased from Loba Chemie Pvt. 
Ltd., Mumbai. 
Preparation of standard stock solution:  
Standard stock solution of drug was prepared by dissolving 
10 mg of drug in 1 ml of DMSO (as the drug is sparingly 
soluble in methanol) and future volume was  made up with 
methanol till 10 ml to get concentration of 1000 µg/ml. From 
this solution 1 ml was taken in 10 ml volumetric flask and 
volume was made up with methanol to get concentration of 
solution 100 µg/ml. Further 1 ml of this solution was diluted 
to 10 ml with methanol to get concentration of solution 10 
µg/ml. 
Selection of detection wavelength: 
From the standard stock solution (1000 µg/ml)further 
dilutions were made using methanol and scanned over the 
range of 220-375 nm against methanol as blank and the 
spectra was obtained. It was observed that the drug showed 
linear, stable and considerable absorbance at 250 nm. 
Representative UV spectrum of Baricitinib is shown in Fig. 2 
 
Figure 2:  UV Spectrum of Baricitinib (10 µg/ml) 
In house preparation of formulation (For Assay) 
Formulation for Baricitinib was prepared by geometric 
mixing of commonly used excipients for tablet formulation 
with drug. All ingredients were accurately weighed and 
geometrically mixed. List of the ingredients is shown in Table 
1. 
Table 1: List of ingredients for in house preparation of 
Formulation 
Name of Ingredient Quantity Taken (for 100mg) 
Baricitinib 2 mg 
Microcrystalline 28 mg 
Mannitol 70 mg 
     
VALIDATION OF THE PROPOSED METHOD: 
The method was validated with respect to linearity, accuracy, 
precision, limit of detection and limit of quantification 
according to the ICH guidelines [5] 
Linearity: 
Standard stock solution of drug was prepared by dissolving 
10 mg of drug in 1 ml of DMSO (as the drug is sparingly 
soluble in methanol) and future volume was  made up with 
methanol till 10 ml to get concentration of 1000 µg/ml.  
Further 1 ml was taken and diluted to 10 ml with methanol 
in volumetric flask to get 100 μg/ml. This solution was 
further diluted with methanol to get range of solution 
containing different concentrations 10-60 μg/ml. 
Absorbance was noted at λ max 250 nm. The equation of 
calibration curve by UV- Spectroscopy was found to be 
y=0.031 x+0.080 with R² = 0.993. The absorbance of drug 
was plotted against the corresponding concentrations to 
obtain the calibration curve as shown in Fig. 3 
 
Fig 3: Linearity curve of Baricitinib by UV- Spectroscopy 
(10-60 µg/ml). 
PRECISION: 
The intraday and interday precision of the proposed method 
were performed by analyzing the corresponding responses 3 
times on the same day and on 3 different days for 3 different 
concentrations of standard solutions of Baricitinib (20, 30 
and 50 μg/ml) without changing the parameters for the 
method. The results were reported in terms of relative 
standard deviation (% RSD). The results obtained for intra-
day and inter-day variations by UV-Spectroscopy are shown 
in Table 2 and Table 3, respectively. 
 
Table 2: Intra-day variation studies data for Baricitinib 
Replicates 
Conc. (µg/ml) 
20 30 50 
 Absorbance 
1 0.715 1.024 1.628 
2 0.709 1.017 1.638 
3 0.708 1.002 1.649 
Average 101.710 100.455 100.542 
SD 0.643 1.235 0.678 
%RSD 0.632 1.229 0.674 
 
 
 
y = 0.0318x + 0.0806 
R² = 0.9935 
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Table 3: Inter-day variation studies data for Baricitinib. 
Replicates 
Conc. (µg/ml) 
20 30 50 
 Absorbance 
1 0.711 1.049 1.627 
2 0.710 1.027 1.648 
3 0.709 1.011 1.659 
Average 101.590 102.008 100.948 
SD 0.113 2.045 1.056 
%RSD 0.111 2.005 1.046 
 
Limit of Detection (LOD) and Limit of Quantification 
(LOQ): 
From the linearity data the LOD and LOQ as calculated, using 
the formula LOD = 3.3 σ/S and LOQ = 10 σ/S, where σ = 
standard deviation of the y intercept of linearity equations 
and S =slope of the calibration curve of the analyte. The LOD 
and LOQ by UV-Spectroscopy were found to be 0.250 μg/ml 
and 0.756 μg/ml, respectively. 
Assay Procedure: 
In house drug formulation was prepared. Quantity of 
formulation equivalent to 10 mg of drug was weighed and 
transferred to 10 ml volumetric flask, dissolved in 1 ml of 
DMSO and volume made to 10 ml with methanol. The 
solution was filtered through Whatmann filter paper and it is 
suitably diluted with methanol to obtain the concentration 
of 10 μg/ml. Procedure was repeated for six times. Results 
obtained are shown in Table 4. 
 
Table 4: Assay of inhouse prepared formulation. 
SN Absorbance 
Amount Recovered 
(µg/ml) 
% Recovery 
1 0.390 10.003 100.026 
2 0.392 10.065 100.655 
3 0.390 10.002 100.019 
4 0.390 10.004 100.039 
5 0.390 10.005 100.055 
6 0.391 10.033 100.329 
Mean 0.391 10.019 100.187 
SD 0.001 0.026 0.258 
%RSD 0.205 0.257 0.257 
 
Accuracy: 
To check the accuracy of the method, recovery studies were 
carried out by addition of standard drug solution to pre-
analyzed sample solution at three different levels 50 %, 100 
% and 150 %. The drug concentrations and % recovery was 
determined from linear equation.  Results obtained are 
shown in Table 5. 
 
Table 5: Accuracy of Baricitinib 
Level 
Conc. of Sample 
solution 
(µg/ml) 
Conc. of Standard 
solution spiked 
(µg/ml) 
Absorbance 
Amount recovered 
(µg/ml) 
 
% recovery ± 
% RSD 
 
50% 10 5 
0.544 14.958 
99.741 ± 
0.376 
0.542 14.906 
0.546 15.019 
100% 10 10 
0.711 20.339 
100.726 ± 
0.833 
0.702 20.058 
0.701 20.039 
150% 10 15 
0.870 25.494 
100.586 ± 
1.514 
0.861 25.206 
0.877 24.739 
 
Robustness: 
Robustness of the method was determined by carrying out 
the analysis under conditions during which detection 
wavelength (± 2 nm) was altered and the effect on the 
absorbance was noted. The method was found to be robust. 
The result of the robustnesss for Baricitinib is shown in 
Table 6 
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Tablet 6: Robustness Study for Baricitinib 
% RSD Found For Robustness Study (Absorbance of 20  µg/ml) 
DETECTION WAVELENGTH (± 2 nm) 
248 250 252  
0.636 0.648 0.635  
 
RESULT AND DISCUSSION: 
In the proposed method, Baricitinib showed absorption 
maxima at 250 nm. The calibration curve was found to be 
linear in the concentration range of 10-60 μg/ml. Accuracy 
was determined by calculating the recovery. Precision was 
calculated as intra and inter day variation (% RSD) for 
Baricitinib. LOD value for Baricitinib was found to be 0.250 
μg/ml and LOQ value is and 0.756 μg/ml respectively. The 
method was successfully used to determine the amounts of 
Baricitiib present in formulation. 
 
Table 7: Summary of Validation Parameters 
Sr. No. Validation parameters Baricitinib 
1. 
Linearity equation 
R2 
Range 
y = 0.031 x + 0.080 
R2= 0.993 
10-60 µg/ml 
2. 
Precision (%RSD) 
Intraday 0.632 – 1.229 % 
Inter-day 0.111 – 2.005 % 
3. Assay 100.187 % 
4. 
Accuracy Mean ± RSD 
50 % 99.741 ± 0.376 
100 % 100.726 ± 0.833 
150 % 100.586 ± 1.514 
5. Limit of detection 0.250 μg/ml 
6. Limit of quantitation 0.756 μg/ml 
7. Specificity Specific 
8. Robustness Robust 
 
CONCLUSION: 
The method proposed in the above study was found to be 
simple, specific, economic, precise and rapid for the 
determination of Baricitinib in bulk as well as in its dosage 
form. Being economic and precise, the developed method 
may conveniently adopted as an alternative method for the 
routine analysis of the Baricitinib in bulk and pharmaceutical 
dosage form. 
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